On September 23, key stakeholders attended an event to celebrate the launch of The Lucy Cavendish Life Sciences Community. The event proved to be a useful forum for members of the community to meet and network and an opportunity to find out more about future plans. The Community is a collaboration of local Cambridge life-science businesses and provides essential funds for STEMM students during their study. It aims to build mutually beneficial, long-term relationships between local businesses, STEMM students, the College and the wider university. During the event, Madeleine Atkins,…
AMSBIO has further expanded its product range to help in the fight against COVID-19 with the introduction of a new range of aptamers targeting SARS-CoV-2 proteins to aid development of new kits and assays.Aptamers are small single-stranded RNA or DNA oligonucleotides that fold in a three-dimensional conformation allowing them to bind specifically to a target. This target can be an organic molecule, free or carried in cells or tissues, or inorganic components, such as metal ions. Aptamers have generated significant interest as promising tools, that compete with monoclonal antibodies, for…
Cambridge, UK, 22 September 2021: Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced that the Company has moved to larger, custom designed laboratory and office premises at Granta Park, Cambridge, UK. The new headquarters will allow the Company to significantly expand its range of services and cell lines.
The 12,000 sq. ft (1,145 m2) facility more than doubles the Company’s laboratory space and has been specifically designed to support the addition of Good Laboratory Practice (GLP) compliant cardiac safety services…
SysMIC is an online course in coding, modelling & data analysis for bioscience researchers.
The next course will start on Monday 1st November 2021
Participants will become confident in using the Python, R and MATLAB platforms, developing interdisciplinary skills that will make them more effective researchers with the confidence to develop and apply computational techniques in modelling and data analysis to their own work.
Our materials were designed by bioscientists, for bioscientists and are focused on biological applications and practical approaches that let participants develop…
San Francisco – Sept. 20, 2021 – Illumina Ventures, an independently-managed, healthcare-focused venture firm, announced today the closing of its second investment fund with total commitments of $325 million, bringing its total capital under management to $560 million. The latest fund is anchored by Illumina, Inc. (Nasdaq: ILMN), with the majority of the total committed capital from other strategic and financial investors, including the Ireland Strategic Investment Fund (ISIF). The fund will support early-stage companies that are pioneering breakthroughs in life science tools, clinical…
Glasgow, UK, 21 September 2021 – Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the appointment of Joshua T. Brumm as its new Independent Chairman, succeeding Satish Jindal.
Amphista’s CEO Dr Nicola Thompson said, “On behalf of the Amphista team I am thrilled to welcome someone of Josh’s calibre to the Board. I look forward to working with Josh as we rapidly develop our pipeline of TPD therapeutics in oncology and beyond and unlock the full therapeutic potential of this exciting new modality. I would also like to thank our…
York, UK, 21 September 2021: The European Laboratory Research & Innovation Group (ELRIG) UK today announced it will launch its equality, diversity, and inclusion (EDI) guiding principles at Drug Discovery 2021. The principles were developed with the support of Equality, Diversity and Inclusion in Science and Health (EDIS), a coalition of organisations working to improve EDI within the science and health research sectors, and the ELRIG community. To promote the initiative, EDIS will host a series of EDI workshops at Drug Discovery 2021—a free-to-attend, in-person event which will take…
- Blackstone portfolio company BioMed Realty acquires 15-acre Cambridge International Technology Park and 27-acre plot at Granta Park in Cambridge- Estimated £850 million investment expected to deliver approximately 800,000 square feet of in-demand Grade A purpose-built lab and office space in Cambridge, creating up to 2,700 jobs- Acquisitions mark vote of confidence from Blackstone in the UK and the growth of the nation’s pioneering life sciences sector, and are supported by BioMed’s 870,000 square feet UK portfolio currently 100% fully leased
SAN DIEGO--(BUSINESS WIRE)--In a major boost to…
We have advised Tyk, a London-based global tech company, on its $35 million growth equity funding round led by new investors Scottish Equity Partners (SEP), alongside existing investors MMC Ventures. Tyk will use the funding to reach new markets and accelerate product development.
Tyk’s innovative API management solution helps to build mission-critical systems in highly regulated industries such as financial services, healthcare, and government. It is used by some of the world’s largest enterprises such as Societe Generale, Starbucks and Domino’s.
With businesses reinventing the way they…
We have advised Artificial Intelligence (AI) company Peak on its Series C funding, which raised $75 million.
This is the second round of funding for Peak in 2021, after completing a $21 million round of Series B funding in February, also advised by Taylor Wessing.
In total the company has raised $119 million, with SoftBank Vision Fund 2 leading Series C, supported by existing investors MMC Ventures, Oxx, Praetura Ventures, Arete and Octopus Ventures.
Our Corporate technology and Life sciences Partner Howard Palmer led the legal team advising on the deal with support from Senior Associate…